iIn Pfizer v. Lee, the Court of Appeals for the Federal Circuit held that a “defective” restriction requirement was sufficient to stop the period of patent term adjustment granted when the U.S. Patent and Trademark Office fails to issue a first action within 14 months from the date an application is filed. Case No. 2015-1265, decided January 22, 2016.
The Defective Restriction Requirement
35 U.S.C. § 154 specifies certain patent term guarantees which, if not met, can serve as bases for a patent term adjustment (PTA). In particular, 35 U.S.C. § 154(b)(1)(A)(i) provides an applicant with a PTA if the U.S. Patent and Trademark Office (USPTO) fails “to provide at least one of the notifications under section 132 or a notice of allowance” no later than 14 months from the application filing date (also known as “A delay”). A notification under 35 U.S.C. § 132 includes rejections, objections and restriction requirements.
In Pfizer, the examiner failed to assign six dependent claims to the groups of separate inventions identified in a first restriction requirement. Pfizer contacted the examiner and informed him of the error in a telephone interview. The examiner acknowledged during the interview that the restriction requirement was defective and agreed to withdraw it and issue a corrected restriction requirement. The question at issue in Pfizer was whether issuance of the defective restriction requirement was sufficient to meet the requirement of a notification under section 132 that would end the period of a delay.
The Court’s Decision
Relying on its decision in Chester v. Miller (906 F.2d 1574 (Fed. Cir. 1990))(“Chester”), the Court found the defective restriction requirement in Pfizer satisfied the requirement of a notification under section 132 because it provided detailed descriptions of the invention groups and sufficient information to which the applicant could have responded. In particular, the Court said Pfizer could have taken direction from the defective restriction requirement because the dependent claims the examiner failed to assign would naturally fall within a group assigned to their respective independent claims. The Court also indicated that Section 814 of the USPTO’s Manual of Patent Examining Procedure provides that a restriction requirement is not automatically invalid because it fails to account for a particular claim.
The Court noted that other courts had reached similar conclusions based on similar facts. For example, the District Court for the District of Columbia held that an examiner’s reissuance of a restriction requirement in response to an applicant’s arguments that it was erroneous does not automatically mean that an application has been “delayed” for the purposes of patent term adjustment. Univ. of Mass. v. Kappos, 903 F. Supp. 2d 77 (D.D.C. 2012)(“UMass”). In addition, the Court distinguished Pfizer from two cases in which applicants successfully obtained additional PTA for defective restriction requirements, because in both cases the examiner sua sponte rescinded and replaced the issued restriction requirements without explanation and without prompting from the applicant. In re: Patent No. 7,803,385, Matthew C. Coffee, Decision on Application For Patent Term Adjustment, May 24, 2012 (“Oncolytics”) and Janssen Pharmaceutica v. Rea, 928 F. Supp. 2d 103 (D.D.C. 2013)(“Janssen”). According to the Court, the applicant’s and examiner’s exchanges in Pfizer were part of the typical “back and forth” process of patent prosecution, and therefore not the type of error for which the PTA statue was intended to compensate.
Judge Newman dissented in Pfizer, arguing that the majority’s holding was in conflict with the intent of the PTA statute to compensate applicants for delay caused by the USPTO. In particular, she disagreed that the majority’s holding did not compensate Pfizer for the delay caused by the defective restriction requirement and in effect required Pfizer to file a speculative response to the restriction requirement despite acknowledgment by the USPTO that the restriction requirement was defective.
Tips for Applicants After Pfizer
Pfizer will make it even more difficult for applicants to obtain additional PTA based on a defective first restriction requirement or office action. However, the Pfizer majority distinguished Oncolytics and Janssen, two cases in which applicants successfully obtained additional PTA for a defective restriction requirement, on the basis that the examiner in those cases voluntarily withdrew the defective restriction requirement without prompting from the applicant. In Oncolytics, the USPTO granted additional PTA where the examiner had agreed to a specific grouping of inventions that the applicant proposed, but then later changed his mind and issued an office action on the merits based on a different grouping of inventions. When granting the additional PTA, the USPTO indicated that the facts of Oncolytics were a “rare occurrence” for which it was appropriate for them to treat as a “non-event” for the purposes of calculating PTA. In Janssen, the first action issued by the examiner was a 185-way restriction requirement. Before the applicant had an opportunity to respond, the examiner issued another action that “rescinded and replaced” the prior action and imposed a three-way restriction requirement on the claims.
When an examiner issues a defective action, applicants should consider whether correction of the PTA is warranted in view of the facts of cases like Oncolytics and Janssen. Correction of the PTA can be petitioned by filing a request at the USPTO within two months of the issuance of a patent (extendible for up to five additional months upon payment of a fee). In addition, the majority in Pfizer expressly declined to hold that the section 132 notification requirement can never be satisfied where the classification of an independent claim is omitted. However, a restriction requirement that is defective for failure to assign an independent claim to an invention group could be more compelling evidence that the restriction requirement fails to meet the section 132 notification requirement, particularly if the disposition of the omitted claim is not clear.
